Shima Karbasi

Shima Karbasi

Auto-generated profile, based on publicly available information

Shima Karbasi

Heart Failure Research Center Isfahan Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MFMohammad Fakhr
Mohammad Fakhr
DSdavood shafie
davood shafie
BMBehrad Manshaee
Behrad Manshaee
SKShima Karbasi
Shima Karbasi
AMAlireza Mazroui
Alireza Mazroui
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
Objective We examined the accuracy of novel anthropometric indices in predicting the progression of prediabetes to diabetes. Subjects and methods This study was performed on the pre-diabetic sub-population from Isfahan Cohort Study (ICS). Participants were followed up from 2001 to 2013. During every 5-year follow-up survey, patients’ data regarding the incidence and time of incidence of diabetes were recorded. We evaluated the association between the risk of developing diabetes and novel anthropometric indices including: visceral adiposity index (VAI), lipid [...] ABSTRACT Objective We examined the accuracy of novel anthropometric indices in predicting the progression of prediabetes to diabetes. Subjects and methods This study was performed on the pre-diabetic sub-population from Isfahan Cohort Study (ICS). Participants were followed up from 2001 to 2013. During every 5-year follow-up survey, patients’ data regarding the incidence and time of incidence of diabetes were recorded. We evaluated the association between the risk of developing diabetes and novel anthropometric indices including: visceral adiposity index (VAI), lipid

6 February 2023 in International Journal of Alzheimer's Disease
Verified
Journal Article
Open access
PDF file
MBMaryam Behzad
Maryam Behzad
NZNegin Zirak
Negin Zirak
GMGhazal Hamidi Madani
Ghazal Hamidi Madani
LBLinda Baidoo
Linda Baidoo
ARAli Rezaei
Ali Rezaei
AIAlzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative
Background. According to recent studies, amyloid-β (Aβ) isoforms as cerebrospinal fluid (CSF) biomarkers have remarkable predictive value for cognitive decline in the early stages of Alzheimer’s disease (AD). Herein, we aimed to investigate the correlations between several targeted proteomics in CSF samples with Aβ ratios and cognitive scores in patients in AD spectrum to search for potential early diagnostic utility. Methods. A total of 719 participants were found eligible for inclusion. Patients were then categorized into cognitively normal (CN), mild cognitive impairment (MCI), and AD and underwent an assessment of Aβ and proteomics. Clinical Dementia Rating (CDR), Alzheimer’s Disease Assessment Scale (ADAS), and Mini Mental State Exam (MMSE) were used for further cognitive assessment. The Aβ42, Aβ42/Aβ40, and Aβ42/38 ratios were considered as means of comparison to identify those peptides corresponding significantly to these established biomarkers and cognitive scores. The diagnostic utility of the IASNTQSR, VAELEDEK, VVSSIEQK, GDSVVYGLR, EPVAGDAVPGPK, and QETLPSK was assessed. Results. All investigated peptides corresponded significantly to Aβ42 in controls. In those with MCI, VAELEDEK and EPVAGDAVPGPK were significantly correlated with Aβ42 ( value < 0.001). Additionally, IASNTQSR, VVSSIEQK, GDSVVYGLR, and QETLPSK were significantly correlated with Aβ42/Aβ40 and Aβ42/38 ( value < 0.001) in this group. This group of peptides similarly corresponded to Aβ ratios in those with AD. Eventually, IASNTQSR, VAELEDEK, and VVSSIEQK were significantly associated with CDR, ADAS-11, and ADAS-13, particularly in MCI group. Conclusion. Our research suggests potential early diagnostic and prognostic utilities for certain peptides extracted from CSF-targeted proteomics research. The ethical approval of ADNI is available at ClinicalTrials.gov with Identifier: NCT00106899.

1 January 2025 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
IVIman Elahi Vahed
Iman Elahi Vahed
YRYasaman Rahimi
Yasaman Rahimi
SKShima Karbasi
Shima Karbasi
ASali safdari
ali safdari
MRMohammad Rahmanian
Mohammad Rahmanian
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a persistent hepatic condition linked with cardiovascular disorders and metabolic disturbances. Characterized by inflammation, fat accumulation, and fibrosis within the liver, MASLD can develop into liver cancer and cirrhosis. With a global prevalence of 32.4%, the condition parallels rising obesity rates. Orlistat inhibits lipase enzymes and, therefore, reduces dietary fat absorption, which may benefit MASLD patients. The present systematic review and meta-analysis were performed in accordance with PRISMA guidelines. Searches of PubMed, Scopus, Web of Science, and Embase up to January 2025 were performed using specific keywords and MeSH terms. Bias assessment and data extraction were conducted using Joanna Briggs Institute (JBI) tools independently by two researchers. Statistical analyses were performed with Stata version 14, calculating standardized mean differences, 95% confidence intervals (CI), and heterogeneity (by performing Cochran’s Q test and I² index). Moreover, metaregression, subgroup analyses, and sensitivity analyses were conducted. Eleven studies featuring 582 participants were included. Orlistat treatment induced a significant reduction in levels of alanine transaminase (ALT) (SMD = -26.23; 95% CI = -34.70 to -17.76) and aspartate aminotransferase (AST) (SMD = -19.62; 95% CI = -28.33 to -10.92). Furthermore, reductions in HOMA-IR, body mass index,cholesterol, insulin, and waist circumference were observed. The included studies exhibited low to moderate heterogeneity for most outcomes, indicating consistent results across trials. Orlistat significantly improved AST, ALT, and some other metabolic parameters in MASLD patients, suggest-ing its potential as an additional treatment option. However, the outcome must be interpreted cautiously, considering study heterogeneity. Further high-quality, multicenter research is necessary to confirm these results.

28 July 2024 in Archives of orthopaedic and trauma surgery
Verified
Journal Article
Closed access
PDF file
AHAmir Human Hoveidaei
Amir Human Hoveidaei
AGAmirhossein Ghaseminejad-Raeini
Amirhossein Ghaseminejad-Raeini
SESina Esmaeili
Sina Esmaeili
MMMohammad Movahedinia
Mohammad Movahedinia
SKShima Karbasi
Shima Karbasi
JCJanet D Conway
Janet D Conway